Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis

British Journal of Haematology

Volumn 152, Issue 2, 2011, Pages 191-200

  Frenzel, Lukas P ^a,b,c   Patz, Michaela ^a   Pallasch, Christian P ^a,b,c,d   Brinker, Reinhild ^a   Claasen, Julia ^a   Schulz, Alexandra ^a   Hallek, Michael ^a,b,c   Kashkar, Hamid ^c   Wendtner, Clemens Martin ^a,b,c  

^a Department I of Internal Medicine ^*  (Germany)

^b Centre of Integrated Oncology   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Chronic lymphocytic leukaemia; Second mitochondria derived activator of caspase mimetic; Therapy; Tumour necrosis factor related apoptosis inducing ligand; X linked inhibitor of apoptosis

Indexed keywords

APOPTOSIS INDUCING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DEATH; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 78650388973     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08426.x     Document Type: Article

References (31)

1. Ashkenazi, A. (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews. Drug Discovery, 7, 1001-1012.
2. Binet, J.L., Caligaris-Cappio, F., Catovsky, D., Cheson, B., Davis, T., Dighiero, G., Dohner, H., Hallek, M., Hillmen, P., Keating, M., Montserrat, E., Kipps, T.J. & Rai, K. (2006) Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, 107, 859-861.
3. Chai, J., Du, C., Wu, J.W., Kyin, S., Wang, X. & Shi, Y. (2000) Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature, 406, 855-862.
4. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42.
5. Dyer, M.J., MacFarlane, M. & Cohen, G.M. (2007) Barriers to effective TRAIL-targeted therapy of malignancy. Journal of Clinical Oncology, 25, 4505-4506.
6. Eckelman, B.P., Salvesen, G.S. & Scott, F.L. (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Reports, 7, 988-994.
7. Fakler, M., Loeder, S., Vogler, M., Schneider, K., Jeremias, I., Debatin, K.M. & Fulda, S. (2009) Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood, 113, 1710-1722.
8. de Graaf, A.O., van Krieken, J.H., Tonnissen, E., Wissink, W., van de Locht, L., Overes, I., Dolstra, H., de Witte, T., van der Reijden, B.A. & Jansen, J.H. (2005) Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. British Journal of Haematology, 130, 852-859.
9. Greco, F.A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G. & Klein, J. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer, 61, 82-90.
10. Grzybowska-Izydorczyk, O., Cebula, B., Robak, T. & Smolewski, P. (2010) Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. European Journal of Cancer, 46, 800-810.
11. Johnstone, R.W., Frew, A.J. & Smyth, M.J. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews. Cancer, 8, 782-798.
12. Jost, P.J., Grabow, S., Gray, D., McKenzie, M.D., Nachbur, U., Huang, D.C., Bouillet, P., Thomas, H.E., Borner, C., Silke, J., Strasser, A. & Kaufmann, T. (2009) XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 460, 1035-1039.
13. Karikari, C.A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., Welsh, K., Reed, J.C., Armour, E.P., Wong, J., Herman, J., Rakheja, D. & Maitra, A. (2007) Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Molecular Cancer Therapeutics, 6, 957-966.
14. Li, L., Thomas, R.M., Suzuki, H., De Brabander, J.K., Wang, X. & Harran, P.G. (2004) A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science, 305, 1471-1474.
15. Loeder, S., Zenz, T., Schnaiter, A., Mertens, D., Winkler, D., Dohner, H., Debatin, K.M., Stilgenbauer, S. & Fulda, S. (2009) A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Research, 69, 8977-8986.
16. Lopez-Guerra, M., Roue, G., Perez-Galan, P., Alonso, R., Villamor, N., Montserrat, E., Campo, E. & Colomer, D. (2009) p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clinical Cancer Research, 15, 2767-2776.
17. MacFarlane, M., Harper, N., Snowden, R.T., Dyer, M.J., Barnett, G.A., Pringle, J.H. & Cohen, G.M. (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene, 21, 6809-6818.
18. MacFarlane, M., Inoue, S., Kohlhaas, S.L., Majid, A., Harper, N., Kennedy, D.B., Dyer, M.J. & Cohen, G.M. (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death and Differentiation, 12, 773-782.
19. Munzert, G., Kirchner, D., Stobbe, H., Bergmann, L., Schmid, R.M., Dohner, H. & Heimpel, H. (2002) Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood, 100, 3749-3756.
20. Natoni, A., MacFarlane, M., Inoue, S., Walewska, R., Majid, A., Knee, D., Stover, D.R., Dyer, M.J. & Cohen, G.M. (2007) TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. British Journal of Haematology, 139, 568-577.
21. Olsson, A., Diaz, T., Aguilar-Santelises, M., Osterborg, A., Celsing, F., Jondal, M. & Osorio, L.M. (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia, 15, 1868-1877.
22. Pallasch, C.P., Schulz, A., Kutsch, N., Schwamb, J., Hagist, S., Kashkar, H., Ultsch, A., Wickenhauser, C., Hallek, M. & Wendtner, C.M. (2008a) Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood, 112, 4213-4219.
23. Pallasch, C.P., Schwamb, J., Konigs, S., Schulz, A., Debey, S., Kofler, D., Schultze, J.L., Hallek, M., Ultsch, A. & Wendtner, C.M. (2008b) Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia, 22, 585-592.
24. Pallasch, C.P., Patz, M., Park, Y.J., Hagist, S., Eggle, D., Claus, R., Debey-Pascher, S., Schulz, A., Frenzel, L.P., Claasen, J., Kutsch, N., Krause, G., Mayr, C., Rosenwald, A., Plass, C., Schultze, J.L., Hallek, M. & Wendtner, C.M. (2009) miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood, 114, 3255-3264.
25. Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N.L., Halpern, W., Corey, A., Calvert, H. & de Bono, J. (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clinical Cancer Research, 13, 6187-6194.
26. Secchiero, P., Tiribelli, M., Barbarotto, E., Celeghini, C., Michelutti, A., Masolini, P., Fanin, R. & Zauli, G. (2005) Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 205, 246-252.
27. Soria, J.C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.P., Reese, D., Wiezorek, J. & Blackhall, F. (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Journal of Clinical Oncology, 28, 1527-1533.
28. Trarbach, T., Moehler, M., Heinemann, V., Kohne, C.H., Przyborek, M., Schulz, C., Sneller, V., Gallant, G. & Kanzler, S. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. British Journal of Cancer, 102, 506-512.
29. Vince, J.E., Wong, W.W., Khan, N., Feltham, R., Chau, D., Ahmed, A.U., Benetatos, C.A., Chunduru, S.K., Condon, S.M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B.A., Koentgen, F., Vaux, D.L. & Silke, J. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell, 131, 682-693.
30. Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., Gschwend, J.E., Simmet, T., Debatin, K.M. & Fulda, S. (2008) Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Research, 68, 7956-7965.
31. Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., Bhanot, U., Hasel, C., Moller, P., Gschwend, J.E., Simmet, T., Debatin, K.M. & Fulda, S. (2009) Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Research, 69, 2425-2434.